高剂量和低剂量甲蓝输液在败血症癌症患者之间的比较研究:一个随机,盲目的,受控的研究
Ehab Hanafy Shaker1, Ahmed Mohamed Soliman2, Ahmed Abd Elmohsen Bedewy3
1Department of Anaesthesia, Intensive care and Pain management, National Cancer Institute, Cairo University, Cairo, Egypt.
在败血症休克患者早期的甲蓝 (MB) 治疗减少了血管压缩剂的使用,并改善了生存率. 与安慰剂相比,4 mg/kg剂量显示出生存优势,MB剂量之间没有显著差异.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 感染性休克是重症监护病房死亡的主要原因之一.
- 早期干预对于改善败血症休克患者的治疗结果至关重要.
- 甲蓝 (MB) 正在作为血管压缩剂的辅助疗法进行研究.
研究的目的:
- 为了评估早期辅助甲蓝 (MB) 的疗效和安全性,在患有败血性休克的癌症患者中.
- 为了比较MB的不同剂量,作为治疗败血症休克时的血管压缩剂的辅助剂.
主要方法:
- 一个双盲,随机对照试验,涉及90名患有败血性休克的患者.
- 三组:安慰剂,1毫克/公斤MB玻尿酸和4毫克/公斤MB玻尿酸,然后进行72小时的输液.
- 主要结局:止血压剂治疗的时间;次要结局:止血压剂剂量,通风日,ICU/住院,死亡率.
主要成果:
- 两组MB (1 mg/kg和4 mg/kg) 与安慰剂相比,血管压缩剂终止的时间显著缩短,血管压缩剂无用日数增加.
- 在1毫克/公斤和4毫克/公斤MB组之间没有观察到结果的显著差异.
- 4毫克/公斤的MB组显示出对死亡率的保护作用 (HR 0.29).
结论:
- 早期的辅助甲蓝疗法在癌症患者的性休克有效地减少了血管压缩剂的依赖性,并增加了血管压缩剂的自由日.
- 在低剂量和高剂量MB玻尿酸剂之间,有效性或不良影响没有显著差异.
- 与安慰剂相比,4 mg/kg的MB玻尿酸剂量表明了生存优势.
更多相关视频
07:51The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
相关概念视频
Blind Procedures
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blinding
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioavailability Study Design: Healthy Subjects Versus Patients
